Kevin Kabler is a partner in Goodwin’s Technology Companies and Life Sciences group. He specializes in building and managing patent portfolios for life sciences companies and institutions, particularly in the fields of immuno-oncology, antibodies, precision medicine, vaccines, genetics, biologics, RNAi, stem cells, and immunotherapy.
His practice involves strategic patent counseling and due diligence for clients at all stages of the business cycle, in addition to analysis and evaluation of third-party patents for mitigation of assertion risks and for investment purposes. He has extensive experience preparing and prosecuting domestic and international patent applications, and advising investors in assessing the competitive landscape, technology and intellectual property assets, and the risks associated with target investments.
Mr. Kabler has a wealth of experience in the natural sciences, with particular experience in immuno-oncology and immunotherapy, including issues involving checkpoint inhibitors, CAR-T cells, and cancer vaccines. He has counseled numerous leading companies, with technologies ranging from antibodies to personalized cancer vaccines, on the protection and exploitation of their intellectual property. Mr. Kabler is also an expert on technology that combines traditional biological and medical research with data science.
Prior to joining Goodwin in 2019, Mr. Kabler was a partner at Fenwick & West LLP. Before joining Fenwick & West, Mr. Kabler was a post-doctoral fellow in the laboratory of Nobel Laureate J. Michael Bishop at the University of California, San Francisco.